 phase II evaluation carboplatin CHIP advanced transitional cell carcinoma urothelium Eastern Cooperative Oncology Group total patients metastatic transitional cell carcinoma systemic therapy randomized phase II evaluation carboplatin cis-dichloro-transdihydroxy-bis-isopropylamine platinum IV CHIP days evaluable patients measurable disease response rates confidence interval carboplatin confidence interval CHIP patients evaluable measurable metastases carboplatin CHIP recipients responses Median survival evaluable patients months months carboplatin months CHIP recipients Independent factors prognostic survival performance status versus liver metastases prior radiation therapy recent weight loss Multivariate analysis performance status liver metastases predictive survival total patients carboplatin CHIP severe life-threatening myelosuppression response rates carboplatin CHIP modest characteristics agents